Pediatrix Acquires Atlanta Maternal-Fetal Physician Practice

  
    
  
  
    
      Pediatrix Medical Group, Inc. (NYSE:PDX) has acquired Maternal Fetal 
      Diagnostic Center of Atlanta, Inc., a physician group that provides 
      services to women with complicated pregnancies.
    
    
      The practice was founded 18 years ago by Phillip L. Potter, M.D., a sole 
      practitioner who sees patients at offices located near two Atlanta area 
      hospitals. The group includes two nurse practitioners as well as 
      clinical and administrative support staff, and Pediatrix will recruit an 
      additional physician to the practice.
    
    
      Dr. Potter has joined Pediatrix to gain additional practice 
      administrative resources to support increasing demand that is coming 
      from a growing referral base, as well as to participate in clinical 
      research.
    
    
      “I’m excited about 
      the opportunities to collaborate on research with maternal-fetal 
      medicine physicians throughout the country to find ways to improve the 
      health of women with high-risk pregnancies,” 
      said Dr. Potter.
    
    
      With the completion of this acquisition, the Company now has a network 
      of more than 120 physicians practicing maternal-fetal medicine and 
      obstetrics across the nation.
    
    
      Pediatrix paid cash for the practice which is expected to contribute to 
      earnings per share immediately. No additional terms of the transaction 
      were announced.
    
    
      Pediatrix has completed seven physician group practice acquisitions 
      during 2008 including one neonatal group, three pediatric cardiology 
      groups, two maternal-fetal groups and one anesthesia group.
    
    
      About Pediatrix
    
    
      Pediatrix Medical Group, Inc. is the nation’s 
      leading provider of neonatal, maternal-fetal and pediatric physician 
      subspecialty services and recently expanded to include anesthesiology 
      services. Pediatrix physicians and advanced practitioners are reshaping 
      the delivery of care within the maternal-fetal, neonatal intensive care 
      and pediatric cardiology subspecialties, using evidence-based tools, 
      continuous quality initiatives and clinical research to enhance patient 
      outcomes and provide high-quality, cost-effective care. Founded in 1979, 
      its neonatal physicians provide services at more than 250 neonatal 
      intensive care units, and in many markets they collaborate with 
      affiliated maternal-fetal medicine, pediatric cardiology physician 
      subspecialists and pediatric intensivists to provide a clinical care 
      continuum. Combined, Pediatrix and its affiliated professional 
      corporations employ more than 1,100 physicians in 32 states and Puerto 
      Rico. Pediatrix is also the nation’s largest 
      provider of newborn hearing screens. Additional information is available 
      at www.pediatrix.com.
    
    
      Certain statements and information in this press release may be 
      deemed to be “forward-looking statements” 
      within the meaning of the Federal Private Securities Litigation Reform 
      Act of 1995. Forward-looking statements may include, but are not 
      limited to, statements relating to our objectives, plans and strategies, 
      and all statements (other than statements of historical facts) that 
      address activities, events or developments that we intend, expect, 
      project, believe or anticipate will or may occur in the future are 
      forward-looking statements. These statements are often characterized by 
      terminology such as “believe”, 
      “hope”, “may”, 
      “anticipate”, “should”, 
      “intend”, “plan”, 
      “will”, “expect”, 
      “estimate”, “project”, 
      “positioned”, “strategy” 
      and similar expressions, and are based on assumptions and assessments 
      made by Pediatrix’s management in light of 
      their experience and their perception of historical trends, current 
      conditions, expected future developments and other factors they believe 
      to be appropriate. Any forward-looking statements in this press release 
      are made as of the date hereof, and Pediatrix undertakes no duty to 
      update or revise any such statements, whether as a result of new 
      information, future events or otherwise. Forward-looking statements are 
      not guarantees of future performance and are subject to risks and 
      uncertainties. Important factors that could cause actual results, 
      developments, and business decisions to differ materially from 
      forward-looking statements are described in Pediatrix’s 
      most recent Annual Report on Form 10-K, including the section entitled “Risk 
      Factors”.